Potent and selective DNA-PK inhibitor (IC50
= 14 nM). Selective for DNA-PK over a range of kinases including mTOR, PI 3-K, ATM and ATR. Potentiates the effects of doxorubicin
(Cat. No. 2252) and etoposide
(Cat. No. 1226) in vitro
and etoposide in vivo
. Also enhances CRISPR-Cas9-mediated homology-directed repair (HDR) efficiency 2 to 3-fold, and decreases nonhomologous end-joining (NHEJ) frequency ~40%.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia.
Willmore et al.
Clin.Cancer Res., 2008;14:3984
Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
Zhao et al.
Cancer Res., 2006;66:5354
Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries.
Leahy et al.
Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing.
Robert et al.
Genome Med., 2015;7:93
The citations listed below are publications that use Tocris products. Selected citations for NU 7441 include:
Showing Results 1 - 10 of 23